Role of TIM-3 in ovarian cancer

• Y. Xu ^[1] ; H. Zhang ^[2] ; Y. Huang ^[1] ; X. Rui ^[1] ; F. Zheng ^[1]
  1. [1] Soochow University

     Soochow University

     China

     
  2. [2] University of South Florida

     University of South Florida

     Estados Unidos

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 9 (September 2017), 2017, págs. 1079-1083
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4+ and CD8+ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer.